Form 4: Coya Therapeutics Director Lee Ann Granted Stock Options

Coya Therapeutics Director Lee Ann was granted 10,000 stock options with an exercise price of $5.65, vesting on January 2, 2027.

Summary

• Lee Ann, a Director of Coya Therapeutics, Inc. (COYA), was granted 10,000 stock options.
• The options have an exercise price of $5.65 per share.
• The grant date for these options was January 2, 2026.
• The options will vest 100% on January 2, 2027, subject to continuous service.
• The expiration date for these stock options is January 2, 2036.
• Following this transaction, Lee Ann beneficially owns 10,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The filing reports a standard compensation event for a director, which is generally viewed as neutral to slightly positive as it aligns interests, but does not provide new fundamental information about the company's operational or financial performance.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.

Future Outlook

The stock options are subject to a vesting schedule, with 100% vesting on the first anniversary of the grant date (January 2, 2027), contingent upon continuous service.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, serving as a form of long-term incentive compensation to align leadership interests with shareholder value creation.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can positively impact shareholders by aligning the director's incentives with the company's long-term success and stock performance.

Next Steps

• The stock options will vest on January 2, 2027, assuming continuous service by the director.

Key Dates

Recommendation

This Form 4 reports a routine stock option grant to a director, which is a standard compensation practice. It does not provide new fundamental information to alter an investment thesis, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Coya Therapeutics, COYA, Stock Options, Director Compensation, Insider Transaction, Equity Grant, Form 4